Business Standard

Torrent Pharma acquires four therapy segment brands from Dr Reddy's

Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company

Pharma Sector, Pharma Companies
Premium

Vinay Umarji Ahmedabad
Ahmedabad-based Torrent Pharmaceuticals said on Thursday it has entered into an agreement to acquire four brands from Dr Reddy's Laboratories Ltd. (DRL). 'Styptovit-E', 'Finast', 'Finast-T', and 'Dynapress' will strengthen Torrent’s presence in the therapy segment.

Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company.

'Finast', 'Finast-T', and 'Dynapress' are used in the treatment of Benign Prostatic Hyperplasia (BPH) and they will aid Torrent's presence in the urology therapy.

The terms of the definitive agreement mandate that Torrent Pharma will take over the manufacturing, marketing, and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in